Can immune thrombocytopenia be cured with medical therapy?

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 4, 2015, Pages 395-404

  Cuker, Adam ^a,b   Prak, Eline T Luning ^b   Cines, Douglas B ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cure; immune thrombocytopenia; remission; treatment

Indexed keywords

AUTOANTIBODY; DEXAMETHASONE; ELTROMBOPAG; EPITOPE; PREDNISONE; RITUXIMAB; THROMBOPOIETIN RECEPTOR; PREDNISOLONE;

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; DISEASE COURSE; DRUG MEGADOSE; EFFECTOR CELL; HUMAN; INNATE IMMUNITY; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; CHRONIC DISEASE; DRUG COMBINATION; DRUG EFFECTS; IMMUNOLOGY; PROCEDURES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

ADAPTIVE IMMUNITY; CHRONIC DISEASE; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNITY, INNATE; PREDNISOLONE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RITUXIMAB;

EID: 84930382840     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1544001     Document Type: Article

References (65)

1. Cuker A., Cines D. B. Immune thrombocytopenia. Hematology (Am Soc Hematol Educ Program): 2010; 2010 377 384
2. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood: 2009; 113 11 2386 2393
3. Donato H., Picón A., Martinez M., et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer: 2009; 52 4 491 496
4. Liebman H. A., Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol: 2007; 14 5 557 573
5. Kojouri K., Vesely S. K., Terrell D. R., George J. N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood: 2004; 104 9 2623 2634
6. Rodeghiero F., Ruggeri M. Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications? Br J Haematol: 2012; 158 1 16 29
7. Hauber A. B., Johnson F. R., Grotzinger K. M., Ozdemir S. Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies. Ann Pharmacother: 2010; 44 3 479 488
8. Bussel J. B., Lee C. S., Seery C., et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica: 2014; 99 7 1264 1271
9. Zaja F., Baccarani M., Mazza P., et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood: 2010; 115 14 2755 2762
10. Stasi R., Stipa E., Masi M., et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med: 1995; 98 5 436 442
11. Sailer T., Lechner K., Panzer S., Kyrle P. A., Pabinger I. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica: 2006; 91 8 1041 1045
12. Pizzuto J., Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood: 1984; 64 6 1179 1183
13. McHeyzer-Williams L. J., McHeyzer-Williams M. G. Antigen-specific memory B cell development. Annu Rev Immunol: 2005; 23 487 513
14. Grimaldi D., Canouï-Poitrine F., Croisille L., et al. Antiplatelet antibodies detected by the MAIPA assay in newly diagnosed immune thrombocytopenia are associated with chronic outcome and higher risk of bleeding. Ann Hematol: 2014; 93 2 309 315
15. McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol: 2007; 44 4 05 S3 S11
16. Cines D. B., Blanchette V. S. Immune thrombocytopenic purpura. N Engl J Med: 2002; 346 13 995 1008
17. Roark J. H., Bussel J. B., Cines D. B., Siegel D. L. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood: 2002; 100 4 1388 1398
18. Jahn S., Niemann B., Winkler T., Kalden J. R., von Baehr R. Expansion of a B-lymphocyte clone producing IgM auto-antibodies encoded by a somatically mutated VHI gene in the spleen of an autoimmune patient. Rheumatol Int: 1994; 13 5 187 196
19. Shlomchik M. J., Craft J. E., Mamula M. J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol: 2001; 1 2 147 153
20. Cines D. B., Cuker A., Semple J. W. Pathogenesis of immune thrombocytopenia. Presse Med: 2014; 43 4, Pt 2 e49 e59
21. Chang M., Nakagawa P. A., Williams S. A., et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood: 2003; 102 3 887 895
22. Tsubakio T., Tani P., Curd J. G., McMillan R. Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura. Br J Haematol: 1986; 63 2 293 300
23. Horikawa K., Martin S. W., Pogue S. L., et al. Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors. J Exp Med: 2007; 204 4 759 769
24. Martin S. W., Goodnow C. C. Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory. Nat Immunol: 2002; 3 2 182 188
25. Leandro M. J. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther: 2013; 15 01 S3
26. Eisenberg R. A., Jawad A. F., Boyer J., et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol: 2013; 33 2 388 396
27. Mahévas M., Patin P., Huetz F., et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest: 2013; 123 1 432 442
28. Liu Y. J., Barthélémy C., de Bouteiller O., Arpin C., Durand I., Banchereau J. Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2. Immunity: 1995; 2 3 239 248
29. Kindler V., Zubler R. H. Memory, but not naive, peripheral blood B lymphocytes differentiate into Ig-secreting cells after CD40 ligation and costimulation with IL-4 and the differentiation factors IL-2, IL-10, and IL-3. J Immunol: 1997; 159 5 2085 2090
30. Tangye S. G., Avery D. T., Hodgkin P. D. A division-linked mechanism for the rapid generation of Ig-secreting cells from human memory B cells. J Immunol: 2003; 170 1 261 269
31. Tangye S. G., Liu Y. J., Aversa G., Phillips J. H., de Vries J. E. Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med: 1998; 188 9 1691 1703
32. Mazzucconi M. G., Francesconi M., Fidani P., et al. Treatment of idiopathic thrombocytopenic purpura (ITP): results of a multicentric protocol. Haematologica: 1985; 70 4 329 336
33. Bellucci S., Charpak Y., Chastang C., Tobelem G. Low doses v conventional doses of corticoids in immune thrombocytopenic purpura (ITP): results of a randomized clinical trial in 160 children, 223 adults. Blood: 1988; 71 4 1165 1169
34. Godeau B., Chevret S., Varet B., et al. French ATIP Study Group. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet: 2002; 359 9300 23 29
35. Newman G. C., Novoa M. V., Fodero E. M., Lesser M. L., Woloski B. M., Bussel J. B. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol: 2001; 112 4 1076 1078
36. Cooper N., Woloski B. M., Fodero E. M., et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood: 2002; 99 6 1922 1927
37. Thompson R. L., Moore R. A., Hess C. E., Wheby M. S., Leavell B. S. Idiopathic thrombocytopenic purpura. Long-term results of treatment and the prognostic significance of response to corticosteroids. Arch Intern Med: 1972; 130 5 730 734
38. DiFino S. M., Lachant N. A., Kirshner J. J., Gottlieb A. J. Adult idiopathic thrombocytopenic purpura. Clinical findings and response to therapy. Am J Med: 1980; 69 3 430 442
39. Portielje J. E., Westendorp R. G., Kluin-Nelemans H. C., Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood: 2001; 97 9 2549 2554
40. Leung A. Y., Chim C. S., Kwong Y. L., Lie A. K., Au W. Y., Liang R. Clinicopathologic and prognostic features of chronic idiopathic thrombocytopenic purpura in adult Chinese patients: an analysis of 220 cases. Ann Hematol: 2001; 80 7 384 386
41. Pamuk G. E., Pamuk O. N., Ba͆lar Z., et al. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol: 2002; 81 8 436 440
42. McMillan R., Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood: 2004; 104 4 956 960
43. Neylon A. J., Saunders P. W., Howard M. R., Proctor S. J., Taylor P. R.; Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol: 2003; 122 6 966 974
44. Cheng Y., Wong R. S., Soo Y. O., et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med: 2003; 349 9 831 836
45. Bae S. H., Ryoo H. M., Lee W. S., et al. High dose dexamethasone vs. conventional dose prednisolone for adults with immune thrombocytopenia: a prospective multicenter phase III trial. Paper presented at: Annual Meeting of the American Society of Hematology; December: 2010;; Orlando, FL
46. Mashhadi M. A., Kaykhaei M. A., Sepehri Z., Miri-Moghaddam E. Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia. Daru: 2012; 20 1 7
47. Borst F., Keuning J. J., van Hulsteijn H., Sinnige H., Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol: 2004; 83 12 764 768
48. Mazzucconi M. G., Fazi P., Bernasconi S., et al. Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood: 2007; 109 4 1401 1407
49. Zaja F., Vianelli N., Volpetti S., et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol: 2010; 85 4 329 334
50. Arnold D. M., Dentali F., Crowther M. A., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med: 2007; 146 1 25 33
51. Auger S., Duny Y., Rossi J. F., Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol: 2012; 158 3 386 398
52. Arnold D. M., Heddle N. M., Carruthers J., et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood: 2012; 119 6 1356 1362
53. Patel V. L., Mahévas M., Lee S. Y., et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood: 2012; 119 25 5989 5995
54. Kuter D. J., Bussel J. B., Newland A., et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol: 2013; 161 3 411 423
55. Saleh M. N., Bussel J. B., Cheng G., et al. EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood: 2013; 121 3 537 545
56. Bussel J. B., Rodeghiero F., Lyons R. M., et al. Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim: report of 9 cases. Paper presented at: Annual Meeting of the American Society of Hematology; December 6, 2011; San Diego, CA
57. Newland A., Cervinek L., Eggermann J., Lefrere F., Kreutzbauer G. Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim-four European case studies. Paper presented at: Annual Meeting of the European Society of Hematology; June 2011; London, United Kingdom
58. Ghadaki B., Nazi I., Kelton J. G., Arnold D. M. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion: 2013; 53 11 2807 2812
59. Mahévas M., Fain O., Ebbo M., et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol: 2014; 165 6 865 869
60. Bao W., Bussel J. B., Heck S., et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood: 2010; 116 22 4639 4645
61. Gómez-Almaguer D., Tarín-Arzaga L., Moreno-Jaime B., et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol: 2013; 90 6 494 500
62. Gudbrandsdottir S., Birgens H. S., Frederiksen H., et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood: 2013; 121 11 1976 1981
63. Gómez-Almaguer D., Herrera-Rojas M. A., Jaime-Pérez J. C., et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood: 2014; 123 25 3906 3908
64. Nazi I., Kelton J. G., Larché M., et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood: 2013; 122 11 1946 1953
65. Carson K. R., Evens A. M., Richey E. A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood: 2009; 113 20 4834 4840